Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has shared an update.
Lumos Diagnostics reported a significant revenue increase in the second quarter of FY25, with a 71% rise to US$2.9 million compared to the previous year. The company also secured a partnership with BARDA for non-dilutive funding to support the FebriDx CLIA waiver trial in the US and received approval for a reimbursement code for FebriDx. Despite operational cash outflows, Lumos’ strategic alliances and successful capital raise position it well for future growth, reflecting its strengthened market positioning and potential impact on stakeholders.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a leader in rapid point-of-care diagnostic technologies. The company focuses on providing diagnostic test and custom reader development services, contract manufacturing, and intellectual property licensing. Their market focus includes partnerships with healthcare companies, such as Hologic, to develop advanced diagnostic products.
YTD Price Performance: 0.0%
Average Trading Volume: 2,032,886
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$33.68M
For an in-depth examination of LDX stock, go to TipRanks’ Stock Analysis page.
